ZA200902592B - Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist - Google Patents

Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist

Info

Publication number
ZA200902592B
ZA200902592B ZA200902592A ZA200902592A ZA200902592B ZA 200902592 B ZA200902592 B ZA 200902592B ZA 200902592 A ZA200902592 A ZA 200902592A ZA 200902592 A ZA200902592 A ZA 200902592A ZA 200902592 B ZA200902592 B ZA 200902592B
Authority
ZA
South Africa
Prior art keywords
receptor antagonist
oral formulations
rapidly disintegrating
thrombin receptor
lyophilized oral
Prior art date
Application number
ZA200902592A
Other languages
English (en)
Inventor
David Monteith
Enrico P Veltri
Srinivas Duggirala
Michael Angelo Falvo
John R Ii Erbey
Kung-I Feng
Anastasia Pavlovsky
Suliman Chawdry
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200902592B publication Critical patent/ZA200902592B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200902592A 2006-09-26 2009-04-15 Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist ZA200902592B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84730606P 2006-09-26 2006-09-26

Publications (1)

Publication Number Publication Date
ZA200902592B true ZA200902592B (en) 2010-03-31

Family

ID=39230776

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200902592A ZA200902592B (en) 2006-09-26 2009-04-15 Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist

Country Status (16)

Country Link
US (1) US20080152712A1 (fr)
EP (1) EP2068823A2 (fr)
JP (1) JP2010504911A (fr)
KR (1) KR20090057400A (fr)
CN (1) CN101541302A (fr)
AR (1) AR062979A1 (fr)
AU (1) AU2007300517A1 (fr)
CA (1) CA2664290A1 (fr)
CL (1) CL2007002759A1 (fr)
CO (1) CO6170417A2 (fr)
MX (1) MX2009003360A (fr)
NO (1) NO20091644L (fr)
PE (1) PE20080673A1 (fr)
TW (1) TWI343262B (fr)
WO (1) WO2008039406A2 (fr)
ZA (1) ZA200902592B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
WO2008079260A2 (fr) * 2006-12-22 2008-07-03 Schering Corporation Promoteurs de désintégration dans des formulations de forme solide obtenues par un procédé de granulation par voie humide
EP2358366A1 (fr) * 2008-11-17 2011-08-24 Schering Corporation Schémas posologiques d'un antagoniste du récepteur de la thrombine basés sur la pharmacocinétique
PL2438060T3 (pl) 2009-06-04 2014-03-31 Merck Sharp & Dohme Aktywny metabolit antagonisty receptora trombiny
EP2440191A2 (fr) 2009-06-08 2012-04-18 Schering Corporation Antagoniste du récepteur de la thrombine et comprimé de clopidogrel à dose fixe
PL2493457T3 (pl) 2009-10-30 2018-01-31 Ix Biopharma Ltd Szybko rozpuszczalna stała postać dawkowana
WO2017134200A1 (fr) 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. Nouvelle composition pharmaceutique à base de vorapaxar et de métoprolol
TR201601548A2 (tr) 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
JPH07116022B2 (ja) * 1989-04-18 1995-12-13 三共株式会社 凍結乾燥製剤の製法
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
ATE311227T1 (de) * 1999-12-01 2005-12-15 Natco Pharma Ltd Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
MXPA02011339A (es) * 2000-05-19 2003-04-25 Amylin Pharmaceuticals Inc Tratamiento del sindrome coronario agudo con glp-1.
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US6645987B2 (en) * 2000-06-15 2003-11-11 Schering Corporation Nor-seco himbacine derivatives useful as thrombin receptor antagonists
ES2232735T3 (es) * 2001-02-23 2005-06-01 Ortho-Mcneil Pharmaceutical, Inc. Compuestos aminometil-pirroloquinazolina que pueden ser utilizados como antagonistas del receptor de la trombina.
PL367130A1 (en) * 2001-05-29 2005-02-21 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
PL371948A1 (en) * 2001-10-18 2005-07-11 Schering Corporation Himbacine analogues as thrombin receptor antagonists
EP2062890B1 (fr) * 2002-04-16 2011-01-05 Schering Corporation Antagoniste de récepteur de thrombine tricyclique
AU2006331583A1 (en) * 2005-12-22 2007-07-05 Schering Corporation Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist

Also Published As

Publication number Publication date
AU2007300517A1 (en) 2008-04-03
WO2008039406A2 (fr) 2008-04-03
KR20090057400A (ko) 2009-06-05
CL2007002759A1 (es) 2008-03-24
CA2664290A1 (fr) 2008-04-03
TW200820995A (en) 2008-05-16
EP2068823A2 (fr) 2009-06-17
TWI343262B (en) 2011-06-11
CO6170417A2 (es) 2010-06-18
CN101541302A (zh) 2009-09-23
NO20091644L (no) 2009-04-24
WO2008039406A3 (fr) 2008-07-03
JP2010504911A (ja) 2010-02-18
AR062979A1 (es) 2008-12-17
MX2009003360A (es) 2009-04-14
PE20080673A1 (es) 2008-06-14
US20080152712A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
ZA200902592B (en) Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
HUS2100003I1 (hu) Angiotenzin receptor antagonista és NEP inhibitor gyógyszerészeti kombinációja
TWI367112B (en) Immediate-release tablet formulations of a thrombin receptor antagonist
EP2098250A4 (fr) Préparation solide se désintégrant oralement
BRPI0821761A2 (pt) Composições de comprimidos de desintegração oral de temazepam
EP2133096A4 (fr) Comprimé à désintégration orale
PT2077729E (pt) Formas orais probióticas
IL194653A0 (en) Lyophilized therapeutic peptibody formulations
IL194355A0 (en) Orally disintegrating tablets
IL194671A0 (en) Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
ZA200702790B (en) Thrombin receptor antagonists
EP2034953A4 (fr) Compositions en couches à désintégration orale
ZA200808247B (en) Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists
HK1133597A1 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
EP2001400A4 (fr) Préparations orales de glycyl-2-méthylpropyl-glutamate
IL202306A (en) Pharmaceutical preparations containing stabilized thrombin
EP2191830A4 (fr) Préparation solide comprenant un antagoniste du récepteur npyy5
ZA200806065B (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
HK1135110A1 (en) Nk1 receptor antagonist composition nk1
IL198760A0 (en) Oral formulations
EP2089019A4 (fr) Polymorphes d'un antagoniste des récepteurs de tachykinine hydro-iso-indolique
GB2453072B (en) Oral care compositions
EP2093290A4 (fr) Mutant de la thrombine
ZA200810854B (en) Oral hygiene
ZA200902164B (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor